Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
SKYE
#4592
Skye Bioscience, Inc. Common Stock
0.772
9
USD
-5.19%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
-5.19%
Changement Mensuel
+17.11%
Evolution sur 6 mois
-3.39%
Changement Annuel
-3.39%
Clôture Précédente
0.815
2
Open
0.786
5
Bid
Ask
Low
0.772
9
High
0.794
0
Volume
30
Marchés
Actions des Marchés US
Soins de Santé
SKYE
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
30.97 M
30.98 M
30.99 M
32.06 M
33.38 M
—
Valuation ratios
Enterprise value
13.26 M
2.84 M
105.69 M
107.54 M
19.14 M
235.22 M
Price to earnings ratio
-3.88
-1.92
-3.91
-3.05
-0.53
-9.4
Price to sales ratio
76.01
413.1
685
467.5
82.43
1 648.03
Price to cash flow ratio
-4.09
-2.05
-4.85
-3.7
-0.69
-11.29
Price to book ratio
1.52
0.22
0.65
0.74
1.48
3.1
Enterprise value to EBITDA ratio
-0.46
-0.08
-2.36
-2.03
-0.34
-4.81
Profitability ratios
Return on assets %
-0.13
-0.17
-0.34
-0.31
-0.51
-1.33
Return on equity %
-0.14
-0.19
-0.4
-0.39
-0.72
-1.7
Return on invested capital %
-496.37
-963.83
-1 421.74
-914.89
-988.55
-4 289.01
Gross margin %
100
—
100
100
100
—
Operating margin %
-7 595.1
—
-20.42 K
-14.51 K
-8 275.9
—
EBITDA margin %
-7 370.28
—
-20.11 K
-14.22 K
-8 075.89
—
Net margin %
-6 940.26
—
-19.72 K
-13.95 K
-8 023.89
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
16.32
11.85
6.09
4.77
3.3
26.01
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0.01
0.01
Solvency ratios
Debt to assets ratio
-0.08
—
—
—
—
—
Debt to equity ratio
-0.09
—
—
—
—
—
Long term debt to total assets ratio
-0.09
—
—
—
—
—
Long term debt to total equity ratio
-0.09
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.22
-0.23
-0.27
-0.34
-0.25
-1.09
EBIT per share
-0.29
-0.3
-0.46
-0.33
-0.37
-1.46
EBITDA per share
-0.28
-0.29
-0.45
-0.33
-0.37
-1.44
Total debt per share
-0.16
—
—
—
—
—
Cash per share
1.88
1.49
1.23
0.89
0.65
4.26
Net current asset value per share
1.94
1.59
1.28
1.01
0.68
4.55
Tangible book value per share
1.87
1.49
1.1
0.83
0.5
3.93
Working capital per share
1.82
1.46
1.07
0.8
0.48
3.79
Book value per share
1.87
1.49
1.1
0.83
0.5
3.93
Nouvelles
Skye Bioscience réduit le prix d’exercice des stock-options et nomme un nouveau directeur financier
Skye Bioscience administre le premier patient de l’étude d’expansion du nimacimab
Skye Bioscience reçoit un avis du Nasdaq pour non-respect du prix minimum
Cantor Fitzgerald maintient sa recommandation Neutre sur Skye Bioscience
Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral
Citizens réitère sa recommandation sur Skye Bioscience après les données sur la perte de poids
Citizens reiterates Skye Bioscience stock rating on weight loss data
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Skye T4 2025 : le nimacimab en combinaison montre 3% de perte de poids supplémentaire
Skye Q4 2025 slides: nimacimab combination shows 3% added weight loss
H.C. Wainwright maintient sa recommandation d’achat sur l’action Skye Bioscience à 20€
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20